Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides an analysis of the enterprise value to revenue forward for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be a financial snapshot from TradingView, highlighting key financial metrics for the company. The content focuses on the valuation of the company from a revenue perspective.
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics, Inc. announced that it granted equity awards to five newly-hired, non-executive employees on July 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's common stock. The options have a 10-year term, an exercise price of $90.21 per share, and vest over four years.
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics, Inc. announced on July 2, 2026, that it granted equity awards to five newly-hired, non-executive employees. These inducement grants, approved by the independent Compensation Committee, were made to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The grants consist of non-qualified stock options for an aggregate of 58,000 shares of common stock with a 10-year term and an exercise price of $90.21 per share.
Dianthus gives 5 new hires stock options worth 58,000 shares
Dianthus Therapeutics granted 58,000 non-qualified stock options to five new non-executive employees on July 1, 2026, as an inducement under Nasdaq Listing Rule 5635(c)(4). These options have a 10-year term, an exercise price of $90.21 per share, and a four-year vesting schedule. This action reflects the company's strategy of using stock options to attract talent and aligns with previous similar grants.
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides a financial metric, "Price to book forward," for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It is presented on the TradingView platform, which offers various financial tools and data for investors. The content is primarily a listing of navigation and footer elements typical of a financial data website.
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial
Dianthus Therapeutics saw its stock rise by 11.4% after initiating the global Phase 3 EMERGE trial for its investigational antibody claseprubart in generalized Myasthenia Gravis (gMG). This follows promising Phase 2 data and FDA Orphan Drug Designation. The trial aims to offer an effective, convenient treatment for gMG patients by targeting the active form of C1s in the classical complement pathway.
Dianthus Therapeutics stock hits 52-week high at 96.85 USD
Dianthus Therapeutics (DNTH) stock has hit a new 52-week high of $96.85, achieving a market capitalization of $5.21 billion and demonstrating significant growth with a 1-year total return of over 440%. Despite an InvestingPro analysis suggesting it may be overvalued, the company's strong performance is supported by positive analyst ratings and the initiation of its Phase 3 EMERGE trial for generalized Myasthenia Gravis. Investment firms like Raymond James, Guggenheim, TD Cowen, and Wolfe Research have reiterated positive ratings, highlighting confidence in its therapeutic developments and market potential.
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com
Dianthus Therapeutics stock has reached a 52-week high of $96.85, pushing its market capitalization to $5.21 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen significant growth with a 440.84% 1-year return and 131% year-to-date gains, reflecting strong investor confidence. This performance follows positive developments including the initiation of its Phase 3 EMERGE trial and reiterated "Buy" ratings from multiple investment firms.
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Dianthus Therapeutics has initiated the Phase 3 EMERGE trial for claseprubart, a treatment for generalized Myasthenia Gravis (gMG). This global, randomized, placebo-controlled study will evaluate subcutaneous doses of claseprubart in approximately 195 participants, with top-line results expected in the second half of 2028. Claseprubart is designed to selectively inhibit the classical complement pathway and has previously shown positive Phase 2 results.
Dianthus launches Phase 3 study of claseprubart in rare muscle disease
Dianthus Therapeutics has initiated the global Phase 3 EMERGE trial for claseprubart in patients with generalized myasthenia gravis (gMG) who are AChR+. This placebo-controlled study will involve approximately 195 participants to evaluate subcutaneous dosing regimens (Q2W and Q4W), building on positive Phase 2 MaGic trial results which showed significant and rapid improvements in gMG symptoms. Top-line results from the EMERGE trial are anticipated in the second half of 2028.
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index
Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell 3000E Index. The company, a clinical-stage biotechnology firm, focuses on developing therapies for severe autoimmune diseases with lead candidates like claseprubart and DNTH212. Recent news includes presentations at healthcare conferences, analyst price target adjustments, and insider stock transactions.
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Growth Benchmark Index
Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell Microcap Growth Benchmark Index. The company is a clinical-stage biotechnology firm developing therapies for severe autoimmune diseases, with its lead candidate, claseprubart, undergoing multiple clinical trials. Recent news includes analyst target adjustments and presentations at healthcare conferences.
Price to sales forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides financial information for Dianthus Therapeutics, Inc. (NASDAQ: DNTH), specifically its price-to-sales forward metric. The content was sourced from TradingView and includes data from ICE Data Services and FactSet.
Price to earnings forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides the "Price to earnings forward" value for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be an unpopulated data point from a financial platform like TradingView, indicating that the specific financial metric is not available for the company at the time of publication. The content primarily consists of navigation and branding elements from the platform.
DNTH - Dianthus Therapeutics Inc Options
This article provides a comprehensive financial snapshot of Dianthus Therapeutics Inc (DNTH), a biotechnology company. It details key financial metrics including market capitalization, revenue, earnings, insider and institutional ownership, profitability ratios, and stock performance data, highlighting its recent price increase and significant year-over-year gains. The data covers various aspects crucial for investors, from valuation multiples to growth rates and analyst recommendations.
Price to book forward of Dianthus Therapeutics, Inc. – DUS:87E
This article provides the "Price to book forward" for Dianthus Therapeutics, Inc. (DUS:87E) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data point from a trading platform.
DNTH Forecast — Price Target — Prediction for 2027
The article provides a forecast for Dianthus Therapeutics, Inc. (DNTH) stock, including a 1-year price target of 127.85 USD based on 13 analysts. It details recent stock performance, analyst estimates for future prices ranging from 98.00 USD to 200.00 USD, and financial metrics such as earnings per share and revenue. Additionally, it offers information on the company's market capitalization, volatility, employee count, and upcoming earnings report date.
Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E)
This article provides an overview of Dianthus Therapeutics, Inc. (FWB:87E) financial actuals and estimates, stock performance, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, and volatility. The company's future earnings, revenue expectations, and current net income are also detailed.
A3ERZ4 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Dianthus Therapeutics, Inc. (A3ERZ4) stock, including analyst price targets, historical performance, and key financial metrics. It details the company's valuation, earnings, revenue, and market capitalization, offering insights into its stock volatility and future outlook. The information is presented as a resource for potential investors to conduct their own research.
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares
Dianthus Therapeutics' SVP and General Counsel, Adam M. Veness, reported an exercise-and-sale transaction involving 30,000 shares of company stock. He exercised stock options at $17.88 per share and subsequently sold the same number of shares in open-market transactions under a Rule 10b5-1 trading plan for weighted average prices of approximately $80.34 and $81.38. Following these transactions, Veness holds no direct common stock but retains 80,000 stock options vesting over four years.
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey outlines the revenue breakdown for Dianthus Therapeutics Inc (DNTH), though it notes that relevant data for FY2025 has not yet been disclosed by the company. It indicates that the company's only reported revenue by region is from the United States, totaling $2.04 million, representing 0.00% of the overall revenue proportion. The article highlights the lack of detailed business segment and regional profit contribution information.
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing
This article reports on a Form 144 SEC filing by Dianthus Therapeutics, Inc. (DNTH), indicating a proposed sale of 30,000 common shares with an aggregate market value of $2,366,400.00. The shares were acquired through the exercise of stock options on June 17, 2026, and are intended to be sold on NASDAQ via Morgan Stanley Smith Barney LLC. The filing shows a neutral impact and sentiment.
Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135
Wells Fargo has reaffirmed its Buy rating for Dianthus Therapeutics (DNTH.US) and maintained its target price at $135. This indicates continued confidence from the financial institution in the company's performance and future outlook.
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics (DNTH) shares have surged 88.9% in the past six months, driven by investor confidence in its lead asset, claseprubart, and strong clinical and financial milestones. Claseprubart is advancing through trials for multiple autoimmune diseases, with key data expected in 2028 and 2026 for its different indications. The company also strengthened its financial position with a $719 million public offering, providing funding into 2030.
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics (DNTH) shares have surged 88.9% in the past six months due to growing investor confidence in its lead asset, claseprubart, and a strong financial position. Claseprubart is being developed for multiple autoimmune diseases, with pivotal phase III studies planned and an early "GO" decision achieved in one study. The company also strengthened its financial position with a recent $719 million public offering, providing funding into 2030.
Dianthus Therapeutics Inc (DNTH) Institutional Confidence
Dianthus Therapeutics Inc (DNTH) has received an institutional shareholding score of 10.00, placing it first within the Biotechnology & Medical Research industry. Institutional ownership currently stands at 99.70%, a slight quarter-over-quarter decrease. Steven Cohen is the largest institutional shareholder, holding 1.18% of outstanding shares.
Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued
Dianthus Therapeutics (DNTH) stock is now considered fairly valued after reporting positive midstage results from its CAPTIVATE Phase 3 trial. The company's stock, at $78.88, has a P/B ratio of 3.6x, which is below the peer average but above the wider US biotech industry average, suggesting a balanced market view despite the company remaining unprofitable. Despite the positive trial results and strong historical performance, risks remain due to ongoing losses and potential clinical setbacks.
Dianthus Therapeutics Inc (DNTH) Earnings Forecast: Future EPS & Revenue Growth Estimates
Dianthus Therapeutics Inc (DNTH) has an earnings forecast score of 9.00, placing it 14th out of 388 in its industry. Analysts have given DNTH a "Strong Buy" rating with a target price of $65.00, suggesting a potential upside of 55.59%. The company's expected revenue for the next quarter is $295.25K, and its EPS for the upcoming quarter is projected at $-0.87.
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Dianthus Therapeutics (DNTH)
Truist Financial analysts have issued bullish sentiments on two healthcare companies: Jazz Pharmaceuticals (JAZZ) and Dianthus Therapeutics (DNTH). Gregory Renza maintained a Buy rating on Jazz Pharmaceuticals, which has a Strong Buy consensus and an 11.6% upside. Danielle Brill also maintained a Buy rating on Dianthus Therapeutics, which holds a Strong Buy consensus with a 68.7% upside potential.
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics Inc. (NASDAQ: DNTH) stock rose significantly on Friday after reporting stronger-than-expected interim results from its CAPTIVATE Phase 3 trial for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The drug demonstrated a 75% confirmed responder rate and a clean safety profile, alleviating concerns about C1s inhibitors in CIDP. An analyst from William Blair reiterated an Outperform rating, noting that the data could strengthen claseprubart’s commercial opportunity, especially following a setback for a rival drug from Sanofi.
DNTH stock clocks best day in over 3 months on strong nerve disorder study results
The article reports that DNTH stock experienced its best day in over three months following the release of strong study results for a nerve disorder treatment. This positive development suggests a significant market reaction to the clinical trial outcomes. The specific details of the study results and their implications for the company's future are the core focus, leading to investor enthusiasm.
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
Dianthus Therapeutics (DNTH) shares surged 8% after reporting positive early data from its late-stage trial of claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP). The company's experimental drug showed a 75% improvement rate in the initial patient group, exceeding expectations. Raymond James reaffirmed its 'Strong Buy' rating with a $125 price target, noting the favorable comparison to Sanofi’s competing drug, which recently discontinued its late-stage study.
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
Dianthus Therapeutics (DNTH) shares jumped 8% after reporting positive early data from its late-stage trial of claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP), with a 75% response rate exceeding expectations. Raymond James reaffirmed its 'Strong Buy' rating and $125 price target, noting the favorable comparison to Sanofi's discontinued competing drug. Dianthus's stock has more than doubled this year, and analysts maintain a strong buy consensus.
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics (NASDAQ: DNTH) stock is trading higher following positive interim results from its CAPTIVATE Phase 3 trial for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The drug showed a 75% confirmed responder rate and a clean safety profile, alleviating concerns about C1s inhibitors in CIDP. An analyst from William Blair reiterated an Outperform rating, noting that a recent Sanofi trial failure for a competing drug strengthens claseprubart's commercial opportunity.
Dianthus Therapeutics (DNTH) details interim Phase 3 CIDP results, Phase 2 gMG data and $1.2B runway
Dianthus Therapeutics released an updated corporate presentation highlighting strong clinical data for its autoimmune pipeline, including interim Phase 3 CAPTIVATE trial results for claseprubart in CIDP showing a 75% response rate, exceeding the 50% target. The company also presented positive Phase 2 MaGic trial data for claseprubart in generalized myasthenia gravis, demonstrating statistically significant improvements across multiple endpoints. Dianthus reported a robust financial position with $1.2 billion in cash and investments as of March 31, 2026, providing a runway into 2030 to support ongoing and future clinical developments across its pipeline, including DNTH212 for rheumatology indications.
Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients
Dianthus Therapeutics (DNTH) announced interim responder data from its Phase 3 CAPTIVATE trial for claseprubart in CIDP, showing a 75% response rate among the first 40 patients. The company reported no serious adverse events, leading to a streamlined Part B of the trial. Top-line results for Part B are expected by year-end 2026, with the company maintaining a strong cash position and advancing other development milestones.
Dianthus Therapeutics Down Over 9%, On Track for Largest Percent Decrease Since January 2025 -- Data Talk
Dianthus Therapeutics (DNTH) stock is experiencing a significant decline, currently down over 9%. This puts the company on track for its largest percentage decrease since January 2025, indicating a notable negative movement in its share price.
Dianthus drops as Sanofi halts trial for peer drug (DNTH)
Shares of Dianthus Therapeutics (DNTH) dropped over 20% in premarket trading after Sanofi (SNY) halted a late-stage trial for its experimental therapy, riliprubart, due to efficacy concerns. Riliprubart is comparable to Dianthus's lead asset, claseprubart, which is also a therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). This news suggests potential concerns for Dianthus's own drug development.
DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution
Dianthus Therapeutics (DNTH) is making strides in neuromuscular and rheumatology treatments with its drug Claseprubart, showing strong efficacy and safety for rapid market entry. The company also has DNTH212 in its pipeline, backed by $1.2 billion in cash, emphasizing efficient execution and market expansion. This information is based on a summary of Dianthus Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
Net debt of Dianthus Therapeutics, Inc. – XETR:87E
This article provides a financial overview of Dianthus Therapeutics, Inc. (XETR:87E), specifically focusing on its net debt. It lists various financial data and services providers without detailing the actual net debt figures. The page appears to be a stub or a section within a larger financial platform.
Net income before discontinued operations of Dianthus Therapeutics, Inc. – XETR:87E
This article displays the net income before discontinued operations for Dianthus Therapeutics, Inc. (XETR:87E). It provides period values, change, and percentage change. The content also includes various financial and trading resources provided by TradingView and other data services.
Gross profit of Dianthus Therapeutics, Inc. – XETR:87E
This article focuses on the gross profit of Dianthus Therapeutics, Inc. (XETR:87E). It presents financial data for the company, indicating various periods, values, and percentage changes related to its gross profit. The content is primarily a data presentation without detailed analysis.
Dianthus Therapeutics, Inc. Balance Sheet – XETR:87E
This article provides a brief overview of Dianthus Therapeutics, Inc.'s financial position (XETR:87E), specifically focusing on its balance sheet. As of Q1 2026, the company reported total assets of 1.08 B EUR, a significant increase from Q4 2025, and total liabilities of 39.44 M EUR. The article includes historical financial data tables for assets, liabilities, and equity, though most entries for years prior to 2025 are currently empty.
Total liabilities & shareholders' equities of Dianthus Therapeutics, Inc. – XETR:87E
This article focuses on the financial data for Dianthus Therapeutics, Inc. (XETR:87E), specifically presenting information related to its total liabilities and shareholders' equities. The content appears to be a stub or a data placeholder from TradingView, offering a framework for financial metrics rather than detailed analysis. It indicates that specific period values and changes would be displayed for the company's liabilities and equity.
Enterprise value of Dianthus Therapeutics, Inc. – XETR:87E
The article provides a financial overview page for Dianthus Therapeutics, Inc. (XETR:87E) on TradingView. It shows the enterprise value of the company and mentions that the market is currently closed with no trades. The content is primarily a structural outline of financial data, market information, and platform features rather than an analytical piece.
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Eases Claseprubart Trial Screening Rules
The FDA's recent easing of safety screening requirements for Dianthus Therapeutics' (DNTH) claseprubart trials has prompted a re-evaluation of the stock's timing, risk, and potential value. Despite this regulatory tailwind, DNTH shares have recently pulled back, though they previously experienced significant year-to-date and one-year gains. Investors are now assessing whether the market has already factored in future growth, given the company's high Price-to-Book ratio compared to the broader US Biotechs industry.
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
Dianthus Therapeutics (DNTH) is seen as a promising mid-cap healthcare stock, with Raymond James reiterating a Strong Buy rating and a revised upside potential for its shares. The company is making significant progress with its drug pipeline, including an orphan drug designation for its claseprubart program and prioritizing DNTH212, which targets autoimmune diseases. Upcoming catalysts include Phase 1 and Phase 2 data expected in 2026, with a Phase 3 study to commence mid-year.
DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth
Dianthus Therapeutics (DNTH) is advancing its drug, Claseprubart, in three neuromuscular indications with pivotal trials underway. Key data readouts are anticipated in 2024 and 2028. The company's competitive trial designs, strong efficacy signals, and robust cash position are expected to support rapid execution and market expansion.
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock By Investing.com
Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, sold approximately $2.4 million worth of company stock after exercising stock options under a pre-arranged trading plan. The transactions involved 26,530 shares sold at prices between $89.17 and $91.96, following their acquisition through options exercise at much lower prices. This comes shortly after Dianthus completed a significant public offering and received updated safety requirements for its clinical trials, alongside maintained "Outperform" and "Overweight" ratings from analysts.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. announced the granting of equity awards to three new non-executive employees on June 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of non-qualified stock options for 60,000 shares with a 10-year term and an exercise price of $89.45 per share, vesting over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent to advance the company's focus on therapies for severe autoimmune diseases.
